Clinical Trials Logo

Charcot Joint of Foot clinical trials

View clinical trials related to Charcot Joint of Foot.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05797259 Completed - Clinical trials for Charcot Joint of Foot

RANKL Antibody for Acute Charcot Neuro-osteoarthropathy

DANCN-CKD
Start date: March 10, 2019
Phase: Phase 4
Study type: Interventional

This study's goal was to determine how denosumab 60 mg, combined with total contact casting and restricted weightbearing status, would affect the treatment of acute CN with CKD. METHODS Participants in the research were those who visited the outpatient foot clinic at PGIMER, CHD in India. During the study period, 446 persons with CN were identified, 102 of whom met the criteria for the first screening, and 78 of whom were ultimately enrolled in the study. Aim: To assess the clinico-radiological remission of Acute Charcot-neuroarthropathy in patients of CKD.

NCT ID: NCT04668755 Completed - Clinical trials for Charcot Joint of Foot

Effect of CROW 3d Printed Sole on Charcot Foot Ulcer

Start date: December 5, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the therapeutic effect of the Charcot Restraint Orthotic Walker three-dimensional printed sole on Charcot foot ulcer healing.

NCT ID: NCT03174366 Completed - Clinical trials for Charcot Joint of Foot

Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy

Start date: May 16, 2017
Phase: Phase 3
Study type: Interventional

Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences frequently lead to below-knee amputation of the affected limb. Currently treatment options are limited, and no pharmaceutical treatment has been efficacious in the medical literature. The purpose of this pilot study is to investigate the potential of the medication denosumab for acute stage Charcot neuroarthropathy.